The patent (No.2685993), entitled "Compositions of adipose tissue-derived secretions for use in the topical treatment or prevention of acne", provides commercial rights in Europe through to 15 March 2032. This is the first Regeneus patent to be granted in Europe and follows the grant of this patent in Australia in October 2014. The patent is also being pursued for grant in other key territories including USA and Japan.
The company's secretions technology utilises the molecules (including cytokines and growth factors) that are secreted by mesenchymal stem cells (MSCs). Regeneus has developed technology and protocols for the production of secretions from MSCs.
The company is exploring partnering options for the development and commercialisation of the secretions technology.
Skin conditions and wound healing are one of the most promising and near term areas for cell-based regenerative medicine products. With few treatment innovations or improvements in the treatment of acne over the last 10 years, the demand for new improved acne treatments is high. Despite this, the global market for acne-based prescription treatments is over $3 billion per annum.
Regeneus CSO, Professor Graham Vesey said, "the granted patent will be specific for the topical treatment of acne, however, we have additional patent applications in the pipeline that cover the use of the secretions technology for other skin conditions".
Regeneus has 49 patents or patent applications across 14 patent families relating to its regenerative medicine development products.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.